To hear about similar clinical trials, please enter your email below
Trial Title:
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
NCT ID:
NCT05991193
Condition:
NSCLC
Conditions: Official terms:
Carcinoma, Non-Small-Cell Lung
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
This is a descriptive observational study, in which data are collected in an
epidemiological fashion and prospective. This study does not intend to intervene the
current medical practice of the recruited patients.
Detailed description:
This is a descriptive observational study, in which data are collected in an EGFR mutant
NSCLC. Our research plan aims to use multi-omics approaches to predict the likelihood of
patients developing brain metastases, assess the prognosis of brain metastasis treatment,
and identify potential biomarkers.
Criteria for eligibility:
Study pop:
Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Patients must be ≥18 years.
- Provision of fully informed consent prior to any study specific procedures.
- Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically.
The mutations above may exist alone or together.
- Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC).
- According to the RECIST 1.1 standard, the patient must have at least one measurable
lesion.
Exclusion Criteria:
- None
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Hunan Cancer hospital
Address:
City:
Changsha
Country:
China
Status:
Recruiting
Contact:
Last name:
Yongchang Zhang, MD
Phone:
+86 731 89762321
Email:
zhangyongchang@csu.edu.cn
Start date:
December 29, 2023
Completion date:
December 31, 2025
Lead sponsor:
Agency:
Hunan Province Tumor Hospital
Agency class:
Other
Source:
Hunan Province Tumor Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05991193
